Download the appMore options
PisaczekSearch
文AEN-US
Public health and WHO

Diabetes for life means steady profits?! The truth about the diabetes drug business

Sources: 12 · Article: 13 379 characters ↓

What do Natural Therapy Specialists write?

Jerzy Jaśkowski

Diabetes is said to create steady demand for medicines because people with a chronic illness keep buying treatments.

„Diabetes creates chronically ill patients and therefore regular buyers of products called medicines, as well as VAT payments—that is, bribes for officials. People with type 2 diabetes, which occurs mainly in older people, can be included in the same group.”Cukrzyca tworzy pacjentów przewlekłe chorych, a więc stałych kupców preparatów, zwanych lekami i płacenie VAT-u, czyli łapówki dla urzędników. Do tego samego grona można wpisać chorych na cukrzycę typu drugiego, czyli występującą głównie u starszych osób.
Jerzy Jaśkowski

Jerzy Jaśkowski presents diabetes websites as advertising for pharmaceutical companies focused on selling medicines.

„These websites are simply advertising for pharmaceutical companies focused on trading in medicines, just like any other goods. Unfortunately, for 100 years bankers have seen an opportunity in illness, one greater than in wars. Besides, it has a completely different humanitarian image.”Te portale są po prostu reklamą koncernów farmakologicznych, nastawionych na handel lekami tak jak każdym innym towarem. Niestety, od 100 lat bankierzy zwietrzyli interes w chorobach, większy aniżeli w wojnach. Poza tym wydźwięk humanitarny jest zupełnie inny.
Jerzy Jaśkowski

Jerzy Jaśkowski writes that some consortia produce both food products and diabetes medicines.

„So far, no medical school, formerly known as an Academy, has called for a ban on adding these halogenated compounds to food products, especially by large Western corporations. In most cases, the manufacturers of drinks and snack bars are the same consortia that produce diabetes medicines. Only the company names are different.”Jak do tej pory żadna wyższa szkoła medyczna, dawniej zwana Akademią, nie wystąpiła z wnioskiem o wprowadzenie zakazu dodawania do produktów spożywczych, szczególnie przez duże koncerny zachodnie, tych chlorowcopochodnych. W większości przypadków producentami napojów czy batoników są te same konsorcja, które produkują leki przeciwcukrzycowe. Tylko nazwy firm są różne.
Jerzy Jaśkowski

Jerzy Jaśkowski links the increase in diabetes cases after statin use to the growing diabetes drug business.

„A 2015 study by the University of Texas found that diabetes cases increased by as much as 87% among patients taking statins. Among people predisposed to diabetes, diabetes complications occurred up to 250% more often. It is worth remembering, however, that pharmaceutical companies can also produce diabetes medicines, and the business will grow.”Badania przeprowadzone przez Uniwersytet w Teksasie w 2015 roku wykazały, że aż o 87% zwiększyło się zachorowanie na cukrzycę o pacjentów otrzymujących statyny. U osób z predyspozycją do cukrzycy, powikłania cukrzycowe wystąpiły aż o 250% częściej. Warto jednak pamiętać, ze koncerny farmaceutyczne także potrafią produkować leki na cukrzycę i biznes będzie rosnąć.
Hubert Czerniak

Hubert Czerniak asks whether professors care about patients or about the interests of pharmaceutical companies.

„In the next issue, I will discuss the complications of diabetes and ways of treating it—how it can be treated here and abroad. Do our professors with academic titles really care about us, or only about the interests of pharmaceutical companies?”W następnym numerze omówię powikłania występujące podczas cukrzycy oraz sposoby leczenia. To jak można leczyć u nas, a jak za granicą. Czy, aby na pewno nasi profesorowie z tytułami naukowymi naprawdę dbają o nas, czy tylko o interes koncernów farmaceutycznych.

What does scientific research from PubMed · Europe PMC say?

We selected 6 studies with the best, positive results. This is a selection, not a full review of all research.

Total number of studies on this topic in PubMed: 1 195.

Aim of the study: To summarize the scientific evidence comparing the safety, efficacy, pharmacokinetics, and pharmacodynamics of biosimilar and reference insulin products.

Results: Of 6945 articles screened, 11 studies were included in the data synthesis. LY2963016, Basalog, Basalin, and MK-1293 were compared to Lantus while SAR342434 was compared to Humalog. Three trials enrolled healthy volunteers, five enrolled type 1 diabetics, and two enrolled type 2 diabetics. One study enrolled both healthy and type 1 diabetics. Of the eleven studies, six examined pharmacokinetic and/or pharmacodynamic parameters and five examined clinical efficacy and immunogenicity. All studies included adverse events. All PK and/or PD studies showed that comparable parameters of biosimilar and reference products were within the pre-specified equivalence margins. Clinical studies suggested similar clinical efficacy and immunogenicity. Adverse events were similar between the groups across all studies.

Money for the studycompany together with others · FDA HHS, U.S. Food and Drug Administration, Johns Hopkins Center of Excellence in Regulatory Science and Innovation
Do the authors have ties to companies?yes — the authors reported it
Did a manufacturer help with the study?YES
Type of studycombined analysis of many studies (meta-analysis)

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Until now most insulin used in developed countries is manufactured and distributed by a small number of multinational companies. Other pharmaceutical companies - many of these are located in countries such as India or China - are also able to manufacture insulin with modern biotechnological methods.

Results: The guidelines already in place in the EU for market approval require that the manufacturer demonstrates that his insulin has a safety and efficacy profile that is similar to that of the 'original' insulin formulation. Recently guidelines for biosimilars were issued in the US; however, these do not cover insulin. Although a challenging approval process for insulins to become BI might be regarded as a hurdle to keep companies out of certain markets, it is fair to say that the potential safety and efficacy issues surrounding BI are substantial and relevant, and do warrant a careful and evidence-driven approval process. Nevertheless, it is very likely that in the next years, BIs will come to the market also in highly regulated markets.

Biosimilar insulins. · Expert Opin Biol Ther 2012
Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: To provide clinicians with an overview of similar biologic products including biosimilars and new insulin versions available in the U.S. and of key issues associated with such products, including differences in manufacturing and regulatory approaches and their impact on clinical use.

Results: Patent protections for many biologics including several insulin preparations have or will expire shortly. This opens the door for new insulin versions to enter the U.S. and global marketplace. The development, manufacturing, and approval process for similar biologic products is more complex than for generic versions of small molecules. Most similar biologic products in the U.S. will be submitted for approval under section 351(k), a newly created biosimilar regulatory pathway. However, some biologics, including new insulin versions, will be submitted via the existing 505(b)(2) regulatory pathway. These regulatory pathways have implications for how such products may be labeled, how they may be dispensed, and how patients may perceive them. The immunogenicity of biologics can affect safety and efficacy and can be altered through subtle changes in manufacturing.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: To evaluate the use of insulin glargine in its licensed basal-bolus indication in terms of both clinical and cost-effectiveness.

Results: Nineteen studies met the inclusion criteria but full reports were available for only six. For type 1 diabetes patients, insulin glargine appears to be more effective than neutral protamine Hagedorn (NPH) in reducing fasting blood glucose (FBG) but not in reducing glycosylated haemoglobin (HbA1c) and there is some evidence that both insulins are as effective as each other in both FBG and HbA1c control. For type 2 patients for whom oral antidiabetic agents provide inadequate glycaemic control, there is no evidence that insulin glargine is more effective than NPH in reducing either FBG or HbA1c and some evidence that both insulins are as effective as each other in both FBG and HbA1c control. Evidence for control of hypoglycaemia is equivocal. In studies where insulin glargine is demonstrated to be superior to NPH in controlling nocturnal hypoglycaemia, this may be only apparent when compared with once-daily NPH and not twice-daily NPH.

Money for the studygovernment, public institutions · National Institute for Health Research (NIHR)
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyreview of many studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Standards allow us to manage expectations for a diverse range of goods and services across the globe. From coordinating international global telecommunications across 24 different time zones to ensuring access to safe drinking water, standards allow us to work, communicate, collaborate, and live with certain expectations about safety and efficacy.

Results: Here we review the value of public standards as applied to the pharmaceutical industry. Using case studies, we demonstrate how standards for complex products, such as biologics, can be created and managed to ensure their optimal value to society while minimizing the burden to the industry. We also discuss the sustainability of standard development and whether there is sufficient transparency to maintain their role in the public trust. Finally, we assess the ability of standards to promote access to reasonably priced and high-quality biosimilars while enabling efficient product development and review.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: 2021 to 2022 marks the one hundredth anniversary of ground-breaking research in Toronto that changed the course of what was, then, a universally fatal disease: type 1 diabetes. Some would argue that insulin's discovery by Banting, Best, Macleod, and Collip was the greatest scientific advance of the 20th century, being one of the first instances in which modern medical science was able to provide lifesaving therapy.

Results: Furthermore, the Toronto work ushered in a century of discovery of the purification, isolation, structural characterization, and genetic sequencing of insulin, all of which influenced ongoing improvements in therapeutic insulin formulations. Here we discuss the body of knowledge prior to 1921 localizing insulin to the pancreas and establishing insulin's role in glucoregulation, and provide our views as to why researchers in Toronto ultimately achieved the purification of pancreatic extracts as a therapy. We discuss the pharmaceutical industry's role in the early days of insulin production and distribution and provide insights into why the discoverers chose not to profit financially from the discovery. This fascinating story of bench-to-beside discovery provides useful considerations for scientists now and in the future.

Money for the studygovernment, public institutions · CIHR
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

What do orthomolecular medicine doctors write?

Orthomolecular Medicine News Service
„Late Systemic Lupus Erythematosus-Associated Insulin Resistance Syndrome: A Rare Cause of De Novo Diabetes Mellitus. Case Rep Med. 2022;2022:4655804. 69. Gehi A, Webb A. Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum. 2003 Apr;48(4):1067-70. 70. Knippenberg A, Robinson GA, Wincup C, Ciurtin C, Jury EC, Kalea AZ. Plant-based dietary changes may improve symptoms in patients with systemic lupus erythematosus. Lupus. 2022 Jan 3;31(1):65. 71. Rondanelli M, Patelli Z, Gasparri C, Mansueto F, Ferraris C, Nichetti M, et al.”Late Systemic Lupus Erythematosus-Associated Insulin Resistance Syndrome: A Rare Cause of De Novo Diabetes Mellitus. Case Rep Med. 2022;2022:4655804. 69. Gehi A, Webb A. Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum. 2003 Apr;48(4):1067-70. 70. Knippenberg A, Robinson GA, Wincup C, Ciurtin C, Jury EC, Kalea AZ. Plant-based dietary changes may improve symptoms in patients with systemic lupus erythematosus. Lupus. 2022 Jan 3;31(1):65. 71. Rondanelli M, Patelli Z, Gasparri C, Mansueto F, Ferraris C, Nichetti M, et al.
Orthomolecular Medicine News Service
„Pharmacological Dependence: While statins and other drugs reduce LDL levels, they do not fully resolve the underlying mechanisms driving cardiovascular disease. A Novel Holistic Approach to ASCVD To improve ASCVD outcomes, we propose a holistic framework based on addressing the root causes, targeting the intermediary mechanisms, and preventing the final outcomes such as plaque formation and cardiovascular events.”Pharmacological Dependence: While statins and other drugs reduce LDL levels, they do not fully resolve the underlying mechanisms driving cardiovascular disease. A Novel Holistic Approach to ASCVD To improve ASCVD outcomes, we propose a holistic framework based on addressing the root causes, targeting the intermediary mechanisms, and preventing the final outcomes such as plaque formation and cardiovascular events.
Orthomolecular Medicine News Service
„Restore metabolic flexibility Reduce refined carbohydrates and added sugars Minimize ultra-processed foods and industrial seed oils Ensure adequate, high-quality protein intake Allow sufficient time between meals to lower basal insulin levels The objective is to improve the body's capacity to shift between glucose and fat utilization without pharmacologic forcing. 2.”Restore metabolic flexibility Reduce refined carbohydrates and added sugars Minimize ultra-processed foods and industrial seed oils Ensure adequate, high-quality protein intake Allow sufficient time between meals to lower basal insulin levels The objective is to improve the body's capacity to shift between glucose and fat utilization without pharmacologic forcing. 2.

Sources (12)

Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.